Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Almeida Costa

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Targeted Oncology|June 30, 2022
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple MyelomaBruno Almeida Costa, Tarek H Mouhieddine, Joshua Richter
Seminars in Hematology|January 29, 2025
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies aheadTarek H Mouhieddine, Bruno Almeida Costa, Joshua Richter
Clinical Pharmacology and Therapeutics|September 26, 2023
CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented ReviewNorah Layla Sadek, Bruno Almeida Costa, Karthik Nath, et al.
American Journal of Hematology|January 25, 2024
Soluble B-cell maturation antigen in multiple myelomaBruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, et al.
Critical Reviews in Oncology/Hematology|May 27, 2023
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectivesBruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, et al.
Journal of Pain and Symptom Management|September 4, 2020
Can Orthodox Jewish Patients Undergo Palliative Extubation? A Challenging Ethics Case StudyCynthia X Pan, Bruno Almeida Costa, Elina K Yushuvayev, et al.
British Journal of Haematology|August 3, 2023
Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysisThomaz Alexandre Costa, Nicole Felix, Bruno Almeida Costa, et al.
American Journal of Hematology|April 12, 2024
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Kevin Pak, et al.
Oncology Research and Treatment|March 7, 2023
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 MutationBruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Targeted Oncology|June 30, 2022
What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple MyelomaBruno Almeida Costa, Tarek H Mouhieddine, Joshua Richter
Seminars in Hematology|January 29, 2025
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies aheadTarek H Mouhieddine, Bruno Almeida Costa, Joshua Richter
Clinical Pharmacology and Therapeutics|September 26, 2023
CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented ReviewNorah Layla Sadek, Bruno Almeida Costa, Karthik Nath, et al.
American Journal of Hematology|January 25, 2024
Soluble B-cell maturation antigen in multiple myelomaBruno Almeida Costa, Ricardo J Ortiz, Alexander M Lesokhin, et al.
Critical Reviews in Oncology/Hematology|May 27, 2023
Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectivesBruno Almeida Costa, Tarek H Mouhieddine, Ricardo J Ortiz, et al.
Journal of Pain and Symptom Management|September 4, 2020
Can Orthodox Jewish Patients Undergo Palliative Extubation? A Challenging Ethics Case StudyCynthia X Pan, Bruno Almeida Costa, Elina K Yushuvayev, et al.
British Journal of Haematology|August 3, 2023
Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysisThomaz Alexandre Costa, Nicole Felix, Bruno Almeida Costa, et al.
American Journal of Hematology|April 12, 2024
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Kevin Pak, et al.
Oncology Research and Treatment|March 7, 2023
Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 MutationBruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, et al.
American Journal of Hematology|March 15, 2024
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysisBruno Almeida Costa, Thomaz Alexandre Costa, Sara Diaz Saravia, et al.
Pageof 4